CClinicalTrials.gg
CompletedNCT02447692PROMIZINGUpdated May 22, 2025

Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study

An interventional study of PSV ventilation strategy and PAV+ ventilation strategy in Critically Ill and Acute Respiratory Failure, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
575
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?

Read the detailed description

Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort.

Modes of Mechanical Ventilation:

Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient.

Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality.

Goal of this Randomized Controlled Trial:

To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.

02

Conditions studied

  • Critically Ill
  • Acute Respiratory Failure

Keywords

  • Proportional Assist Ventilation
  • Pressure Support Ventilation
  • Weaning
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's enrollment of 575 is above the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 309 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized.

A. SCREENING INCLUSION CRITERIA:

  • A1. Age 18 years or older
  • A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours

A. SCREENING EXCLUSION CRITERIA:

  • A3. Anticipating withdrawal of life support and/or shift to palliation as the goal of care
  • A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causing elevated intracranial pressure, or impaired control of breathing, or requiring specific ventilator adjustments (i.e. To attain specific CO2 target) or requiring neurosurgical intervention
  • A5. Known or suspected severe or progressive neuromuscular disorder likely to result in prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome, Myasthenia Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or other restrictive disorder) (Note that obesity hypoventilation syndrome that may be managed with nocturnal non-invasive ventilation is NOT an exclusion under A5)
  • A6. Severe COPD: Baseline daytime hypercapnia (pCO2> 50 mmHg) OR GOLD 4 airflow limitation (FEV1\<30% predicted) OR MRC class 4 symptoms ("I am too breathless to leave the house" OR "I am breathless when dressing")
  • A7. Broncho-pleural fistula
  • A8. Tracheostomy present at ICU admission for the purpose of chronic or prolonged mechanical ventilation (>21 days). (Note that a patient who was endotracheally intubated for acute respiratory failure and received a tracheostomy during their ICU admission, prior to enrolment, is not excluded under A8).
  • A9. Current enrolment in a confounding study, as assessed by the steering committee
  • A10. Previous randomization in the PROMIZING Study
  • A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g. interstitial lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likely to result in prolonged or chronic ventilator dependence /unlikely to wean from mechanical ventilation [Note: patients who are candidates for intervention to treat the underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant, cardiac surgery) may be re-evaluated once intervention is complete and they no longer meet criteria A11.]

B. ENROLMENT INCLUSION CRITERIA:

  • B1. Ability or potential ability to trigger ventilator breaths (i.e. not receiving neuromuscular blockade).
  • B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateau pressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Control pressure-controlled ventilation or similar mode: Pressure control plus PEEP ≤ 30 cm H2O OR On Pressure Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR On Proportional Assist ventilation: PAV gain \<85%
  • B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O
  • B4. Metabolic disorders corrected: pH ≥7.32
  • B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6 hours
  • B6. Anticipate ongoing need for ventilation >24 hours

B. ENROLMENT EXCLUSION CRITERIA:

  • B7. Extubated
  • B8. Died
  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients on ECMO.)
  • B10. Patient transferred to a non-participating centre

B. ENROLMENT DEFERRAL CRITERIA:

  • B11. Plan to extubate/discontinue mechanical ventilation within \<24 hours (Reassess within 24 hours)
  • B12. Patient currently on ECMO (Reassess patient once off ECMO)
  • C9: Plan for surgery or complex procedure that will require full ventilation to be done prior to attempting extubation (e.g. Procedure requiring neuromuscular blockade and/or heavy sedation, such that patient would be apneic, or not be able to trigger ventilator) (Reassess after surgery/procedure complete)

C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:

  • C2. Upon review of Screening and Enrolment criteria (A and B), the patient still passes.
  • C3. Treating physician has provided verbal consent to proceed with standardized tests and randomization if eligibility criteria are met.

C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:

  • C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine >0.5 ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressor within 6 hrs
  • C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours)
  • C8. Unstable arrhythmias (HR>140 or \<50) with clinical signs of low cardiac output or or SBP\<80 mmHg
  • C10. Receiving a "strict lung protective" ventilation strategy for ARDS (eg. Order on chart to keep Vt ≤6 mL/kg PBW)

C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:

  • C12. Treating physician has declined consent

D. WEANING CRITERIA:

  • D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O
  • D2. pH ≥7.32
  • D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min or equivalent.

In the final stage (E), patients will be considered eligible for randomization if the following criteria are met.

E. RANDOMIZATION INCLUSION CRITERIA:

  • C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patient incapable and no SDM available to provide consent within the randomization window
  • E1. Upon review of Criteria A, B, and C, the patient still passes and the patient has passed the PST.
  • E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT

E. RANDOMIZATION EXCLUSION CRITERIA:

  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressure support of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It is acceptable to include a patient who has been tried on pressure support or proportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients while on ECMO
  • C4. Patient/SDM has declined consent
  • C5. Patient incapable and no SDM available to provide consent (not applicable if plan to obtain deferred consent)
  • E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes
  • E4. Approval withdrawn (by physician or patient/SDM)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
575 participants (actual)

Study arms

  • Active comparator
    PSV ventilation strategy

    The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.

    Other: PSV ventilation strategy

  • Active comparator
    PAV+ ventilation strategy

    The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.

    Other: PAV+ ventilation strategy

Interventions

  • OtherPSV ventilation strategy

    An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria

  • OtherPAV+ ventilation strategy

    An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria

06

What researchers measure

Primary outcomes

  1. Time from randomization to successful liberation from invasive mechanical ventilation.

    "Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.

    Time frame: up to 90 days

Secondary outcomes

  1. Ventilator-free days at 14, 21 and 28 days post randomization

    "Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.

    Time frame: 14, 21 and 28 days post randomization

  2. Time from randomization to live ICU discharge (up to day 90)

    Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.

    Time frame: up to 90 days

  3. Time from randomization to live hospital discharge (up to day 90)

    Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.

    Time frame: up to 90 days

  4. Mortality

    Measured as time to death, ICU mortality; hospital mortality; 21, 28, and 90 day mortality

    Time frame: up to 90 days

  5. Weaning Progress

    Measured as time from randomization to: first SBT; first successful SBT; first extubation

    Time frame: up to 90 days

  6. Weaning Difficulties

    Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)

    Time frame: 90 days

  7. Weaning Complications

    Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)

    Time frame: 90 days

  8. Tolerance of modes

    Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization

    Time frame: 90 days

  9. Serious Adverse Events

    Incidence of reported serious adverse events

    Time frame: 90 days

Other outcomes

  1. Co-interventions

    Co-interventions will be monitored and described including use of sedating medications

    Time frame: 28 days

  2. Subgroup analyses based on: (a) duration of MV prior to randomization as a continuous variable or as a binary variable of greater than 5 days

    Identifies a subgroup of patients at time of randomization who are at risk for prolonged weaning

    Time frame: At randomization

  3. Subgroup analyses based on (b) failing an SBT prior to randomization vs. failed CPAP 0 trial vs. failed weaning criteria prior to randomization

    Identifies a subgroup of patients at time of randomization classified as difficult weaning vs. failed CPAP 0 trial vs. failed weaning criteria prior to randomization

    Time frame: At randomization

  4. Subgroup analyses based on (c) failed extubation prior to randomization

    Identifies a subgroup of patients at time of randomization classified as having "difficult weaning".

    Time frame: At randomization

  5. Subgroup analyses based on (d) mild vs. moderate vs. severe frailty

    Differentiates between severely frail and less frail

    Time frame: At ICU admission

  6. Subgroup analyses based on COVID-19 positive test

    Differentiates between COVID-19 positive and COVID-19 negative

    Time frame: At ICU admission

  7. Subgroup analyses based on tracheostomy present at randomization

    Identifies a subgroup of patients at risk of prolonged weaning

    Time frame: At randomization

07

Study locations

22 sites
  • El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"
    Buenos Aires, C1430EFA, Argentina
  • Kingston General Hospital
    Kingston, Ontario, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Victoria Hospital
    London, Ontario, Canada
  • Sunnybrook Hospital - Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • North York General Hospital
    Toronto, Ontario, Canada
  • St. Michael's Hospital
    Toronto, Ontario, Canada
  • UHN- Toronto General Hospital
    Toronto, Ontario, Canada
  • UHN- Toronto Western Hospital
    Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM)
    Montréal, Quebec GC6R+GW, Canada
  • Royal Victoria Hospital
    Montréal, Quebec, Canada
  • Institut Universitaire de cardiologie et de pneumologie de Quebec
    Québec, Quebec, Canada
  • Centre Hospitalier Universitaire (CHU) de Angers
    Angers, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, QFW8+H5, France
  • Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)
    Créteil, France
  • Hôpital Universitaire Pitié-Salpêtrière
    Paris, France
  • Centre Hospitalier Universitaire (CHU) de Rouen
    Rouen, France
  • University Hospital of Heraklion
    Heraklion, Greece
  • University Hospital of Ferrara
    Ferrara, Italy
  • San Giovanni Battista University Hospital
    Turin, Italy
  • King Abdulaziz Medical City
    Riyadh, 11426, Saudi Arabia
  • Hospital de Sant Pau
    Barcelona, Spain
08

References and documents

Study documents

  • Study protocol · Dec 1, 2019
  • Statistical analysis plan · Jul 8, 2024
  • Statistical analysis plan · Jul 26, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data will be collected electronically and stored at the Clinical Coordinating Center at the Applied Health Research Centre (AHRC). A de-identified database of all data may be made available for use 3 years after the primary publication upon request and review of the statistical analysis plan by the PROMIZING steering committee.

Supporting information: Study protocol, Sap, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02447692
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators
Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group
Responsible party
Sponsor
First posted
May 19, 2015
Start date
Sep 14, 2016
Primary completion
Jul 16, 2024
Completion
Jul 16, 2024
Last update
May 22, 2025

Study contacts

Karen J Bosma
principal investigator · London Health Sciences Centre, London, Ontario, Canada
Laurent Brochard
principal investigator · St. Michael's Hospital, Toronto, Ontario, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion